^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)

    i
    Other names: NTRK3, TRKC, Neurotrophic tyrosine kinase, receptor, type 3
    1d
    Secretory carcinoma of the breast: a report of six cases with different immunophenotypes and molecular subtypes. (PubMed, Histopathology)
    These findings support the existence of greater variability in surrogate and intrinsic molecular subtypes within secretory carcinomas, providing potential personalized therapeutic strategies for the treatment of these patients.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
    |
    HER-2 expression
    1d
    TFG-Containing Fusions in Melanocytic Tumors: From Polymorphic Read-Through Transcripts to Oncogenic Kinase Fusions. (PubMed, J Cutan Pathol)
    Recognition of such fusions is essential to avoid misinterpretation, particularly as fusion detection increasingly informs diagnosis and clinical decision-making. These findings underscore the necessity of integrating molecular results with established clinicopathologic frameworks.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ADGRG7 (Adhesion G Protein-Coupled Receptor G7)
    2d
    A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
    P1/2, N=67, Recruiting, D3 Bio (Wuxi) Co., Ltd | Active, not recruiting --> Recruiting | Trial completion date: Apr 2028 --> Aug 2028 | Trial primary completion date: Apr 2028 --> Aug 2028
    Enrollment open • Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    BRAF V600E • EGFR mutation • KRAS G12C • BRAF V600 • EGFR L858R • EGFR T790M • KRAS G12D • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • ROS1 fusion • EGFR G719X • MET mutation • EGFR S768I • RET rearrangement • KRAS G12 • KRAS G12S • KRAS Q61
    |
    D3S-002 • elisrasib (D3S-001)
    2d
    One case of facial salivary gland secretory carcinoma and a literature review. (PubMed, Int J Surg Case Rep)
    ETV6-NTRK3 gene translocation is the most reliable basis for diagnosing SC. Combining morphological diagnosis with gene testing is not difficult.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • MUC4 (Mucin 4, Cell Surface Associated) • ANO1 (Anoctamin 1)
    6d
    Discovery of a sulfotyrosine-motif in the human TrkB extracellular domain required for agonist activation. (PubMed, bioRxiv)
    Our findings reveal unique features of TrkB, not present in the related neurotrophin receptors TrkA and TrkC, and suggest new directions to explore the role of sulfotyrosine in TrkB signalling and identify new TrkB-specific protein ligands. Investigation of the mechanism of action of TrkB agonist ZEB85 extends molecular understanding of TrkB activation.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    8d
    An integrative mendelian randomisation and drug mechanism framework for target prioritisation and therapeutic repurposing in major depression. (PubMed, Transl Psychiatry)
    Ten high-priority targets of brain-penetrating compounds included ACE and NISCH (cardiovascular drugs), NDUFA2, NDUFB6, and NDUFS1 (metformin), CDK4, NTRK3, and MET (oncology inhibitors), and GLS and NOS2 (enzyme inhibitors). We found genetic evidence for established and novel MD targets across the drug development pipeline. Novel targets point to mechanisms beyond monoaminergic systems, most with approved drugs for other conditions, offering immediate repurposing opportunities.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • CDK4 (Cyclin-dependent kinase 4) • NOS2 (Nitric Oxide Synthase 2) • NDUFA2 (NADH:Ubiquinone Oxidoreductase Subunit A2) • NDUFS1 (NADH:Ubiquinone Oxidoreductase Core Subunit S1)
    |
    metformin
    12d
    Rapid On-Site Next-Generation Sequencing: An Alternative to Single-Gene and Send-Out Testing in Non-Small Cell Lung Cancer and Colorectal Cancer in a Community Pathology Laboratory Setting. (PubMed, J Mol Diagn)
    In CRC, TAT was 4.1, 5.3, and 10.2; QNS 0%, 0%, 7.5%; detection 63.9%, 62.5%, and 57.1%. OPA provides faster TAT and lower QNS rates with comparable detection of actionable alterations, supporting its use for community-based molecular testing in NSCLC and CRC.
    Journal • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • HER-2 mutation • RET fusion • MET exon 14 mutation • ALK fusion • ALK mutation • ROS1 fusion • KRAS G12
    |
    Oncomine Precision Assay
    14d
    STARTRK-2: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (clinicaltrials.gov)
    P2, N=534, Active, not recruiting, Hoffmann-La Roche | Trial completion date: May 2026 --> Jun 2027 | Trial primary completion date: May 2026 --> Jun 2027
    Trial completion date • Trial primary completion date • Pan tumor
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    ALK rearrangement • ROS1 rearrangement
    |
    Xalkori (crizotinib) • Rozlytrek (entrectinib)
    14d
    Differences Among Genomic Profiling Tests for Bone and Soft-Tissue Sarcomas in a Universal Health Insurance System. (PubMed, J Bone Joint Surg Am)
    In this cohort, the DNA+RNA-based panel showed a higher detection rate for TK fusions, although the panels were applied to different patient groups and the sensitivity and specificity could not be determined. Future studies evaluating different test types on the same tumor specimens are warranted to clarify whether the dual-sequencing approaches can improve the identification of actionable genetic events.
    Reimbursement • US reimbursement • Journal
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • EML4 (EMAP Like 4) • FGFR1 (Fibroblast growth factor receptor 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase) • RBPMS (RNA-binding protein with multiple splicing)
    |
    ALK fusion • NTRK fusion
    |
    FoundationOne® CDx • OncoGuide™ NCC Oncopanel System
    |
    Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)
    14d
    Secretory carcinoma in the parotid gland: A case report. (PubMed, Mol Clin Oncol)
    Both patients received postoperative radiotherapy at a total dose of 60 Gy. No evidence of local recurrence or distant metastasis has been observed during the follow-up period of 7 years in case 1 and 3 years in case 2.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • SCGB2A2 (Secretoglobin Family 2A Member 2)
    15d
    Mutational Landscape and Treatment Response in Extensive-Stage Small-Cell Lung Cancer: A Single-Center Real-World Analysis. (PubMed, Curr Oncol)
    Baseline adrenal metastasis serves as a poor prognostic indicator. Distinct genomic mutation signatures are associated with clinical characteristics, suggesting potential pathways for personalized treatment strategies.
    Retrospective data • Journal • Real-world evidence • IO biomarker
    |
    ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • SMAD4 (SMAD family member 4)
    |
    PIK3CA mutation
    21d
    Detection of NTRK gene fusions in sarcomas: a comparative study of Pan-TRK immunohistochemistry, FISH, and RNA-Based NGS. (PubMed, Pathologica)
    FISH may represent a useful intermediate diagnostic tool when NGS is unavailable but requires cautious interpretation particularly in cases with atypical or isolated signals. NGS-based molecular confirmation remains essential for the definitive identification of NTRK fusions.
    Clinical • Retrospective data • Journal • Next-generation sequencing
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • BCOR (BCL6 Corepressor) • EWSR1 (EWS RNA Binding Protein 1) • NTRK (Neurotrophic receptor tyrosine kinase) • NACC2 (NACC Family Member 2)
    |
    NTRK positive • NTRK fusion